The profits came from vaccines like Shingrix, which protects elderly patients in affluent countries against shingles. Many of the larger pharmaceutical firms preferred to exit the high-cost and high-profile business, but those that remained were now flanked by smaller biotech outfits and low-cost vaccine manufacturers from the developing world, notably India. By the 2010s, two-thirds of the world’s children were vaccinated with jabs produced by India’s Serum Institute.
